An Open-Label Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

Trial Profile

An Open-Label Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Rovalpituzumab tesirine (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Sponsors AbbVie
  • Most Recent Events

    • 28 Feb 2018 Planned End Date changed from 27 Jun 2018 to 25 Mar 2020.
    • 31 Jan 2018 Planned end date changed from 25 Mar 2020 to 27 Jun 2018.
    • 31 Jan 2018 Planned primary completion date changed from 5 Jul 2019 to 2 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top